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Susceptibilities to fourteen antimicrobial agents important in clinical medicine and agriculture were deter-
mined for 752 Escherichia coli isolates of serotypes O26, O103, O111, O128, and O145. Strains of these
serotypes may cause urinary tract and enteric infections in humans and have been implicated in infections
with Shiga toxin–producing E. coli (STEC). Approximately 50% of the 137 isolates from humans were
resistant to ampicillin, sulfamethoxazole, cephalothin, tetracycline, or streptomycin, and approximately
25% were resistant to chloramphenicol, trimethoprim-sulfamethoxazole, or amoxicillin-clavulanic acid.
Approximately 50% of the 534 isolates from food animals were resistant to sulfamethoxazole, tetracycline,
or streptomycin. Of 195 isolates with STEC-related virulence genes, approximately 40% were resistant to
sulfamethoxazole, tetracycline, or streptomycin. Findings from this study suggest antimicrobial resistance
is widespread among E. coli O26, O103, O111, O128, and O145 inhabiting humans and food animals.  
he emergence and dissemination of antimicrobial resis-
tance in bacteria has been well documented as a serious
problem worldwide (1). Selective pressure favoring antimicro-
bial-resistant phenotypes is applied whenever antimicrobials
are used, including treating disease in clinical medicine and
preventing disease and promoting growth in animal husbandry.
As a consequence, antimicrobial-resistant bacteria are selected
for, thereby posing a critical public health threat in that antimi-
crobial treatment efficacy may be reduced. 
Escherichia coli are facultative anaerobes in the normal
intestinal flora of humans and animals (2,3); however, patho-
genic strains of these bacteria are an important cause of bacte-
rial infections. In humans, these strains are the foremost cause
of urinary tract infections (4), as well as a major cause of neo-
natal meningitis (5), nosocomial septicemia, and surgical site
infections (6). Infection with Shiga toxin–producing E. coli
(STEC) may also result in complications including thromb-
ocytopenic purpura, severe hemorrhagic colitis, and hemolytic
uremic syndrome (7). While therapeutic options vary depend-
ing on the type of infection, antimicrobials including trimetho-
prim-sulfamethoxazole, fluoroquinolones, and third-
generation cephalosporins are generally recommended for
treating infections caused by E. coli other than STEC (6). In
contrast, because these antimicrobials may increase levels of
free Shiga toxin in vivo, thus facilitating disease progression,
the usefulness of antimicrobials in treating STEC infection
remains less clear (6,8). 
Recent reports have suggested the use of tetracyclines,
sulfa drugs, cephalosporins, and penicillins to be a major fac-
tor in the emergence and dissemination of antimicrobial-resis-
tant E. coli (9–14). However, a relative paucity of information
exists regarding antimicrobial resistance in E. coli from non-
hospital sources, especially those from animal sources. In this
study, antimicrobial susceptibility profiles were determined for
E. coli isolates of serotypes O26, O103, O111, O128, and
O145. Strains of these serotypes may cause urinary tract and
enteric infections in humans and have been implicated in
infections with STEC (15–19). The isolates were originally
gathered from diverse sources, including food animals, com-
panion animals (i.e. dogs, cats, and rabbits), and humans. Our
primary objective was to characterize the extent of antimicro-
bial resistance in these E. coli serotypes from agricultural and
clinical settings. 
Methods
Bacterial Strains
We included 752 E. coli isolates from the collection of The
Pennsylvania State University’s E. coli Reference Center in
the study (Table 1); this center provides characterization of E.
coli isolates submitted from outside sources.  Sixty-eight iso-
lates from humans were submitted to the E. coli Reference
Center from 9 U.S. states, 45 from Saudi Arabia, 13 from
Argentina, 4 from Canada, 3 from Mexico, 3 from Zambia,
and 1 from Singapore. Two hundred forty-eight isolates from
cattle were submitted from Michigan, 56 from Iowa, 33 from
Pennsylvania, 65 from 13 other U.S. states, and 2 from Can-
ada. Fifty-one isolates from turkeys were submitted from 13
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U.S. states. Forty-five isolates from chickens were submitted
from 10 U.S. states, 2 from Canada, and 2 from India. Twenty-
two isolates from swine were submitted from 7 U.S. states, 3
from South Korea, and 1 from India. Seventy-four isolates
from nonfood animals were submitted from 20 U.S. states, 5
from Paraguay, and 2 from Hungary. We classified nonfood
animals as those not commonly used in food production,
including rabbits (19 E. coli isolates), hamsters (8 isolates),
deer (7 isolates), horses (7 isolates), dogs (7 isolates), alpacas
(5 isolates), okapi (4 isolates), parrots (4 isolates), sheep (4
isolates), antelope (4 isolates), mice (3 isolates), seagulls (2
isolates), a cat (1 isolate), a goat (1 isolate), a llama (1 isolate),
a marmoset (1 isolate), a mink (1 isolate), a rat (1 isolate), and
a turtle (1 isolate).
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing of all isolates was done
with broth microdilution using the PASCO MIC/ID system
(Becton, Dickinson and Company, Sparks, MD). Testing was
done according to manufacturer’s instructions and according
to guidelines developed by the National Committee for Clini-
cal Laboratory Standards (NCCLS) (20). Tested antimicrobi-
als, dilution ranges, and resistance breakpoints are listed in
Table 2.  Ceftiofur- and cefoxitin-resistant isolates were fur-
ther examined for production of extended-spectrum-β -lacta-
mases (ESBLs) with disk diffusion according to NCCLS
standards (21).
Detection of Virulence Genes
Isolates were grown at 37°C overnight on veal infusion
agar (Becton, Dickinson and Company). A loopful of culture
was resuspended in 200 µL of distilled water, incubated at
99°C for 15 min, and centrifuged at 12,000 x g for 2 min. The
supernatant was used as a template for amplification of Shiga
toxin genes (stx1 and stx2), the intimin gene (eae), and the
enterohemolysin A gene (hlyA) through multiplex polymerase
chain reaction (PCR) (22). Primers described by Witham et al.
(23) and Paton (24) were used for amplification of stx1 and
stx2, respectively; those described by Gannon et al. (25) were
used for amplification of eae; and those described by Fagan et
al. (26) were used for amplification of hlyA. Each 11-µL PCR
contained 37.5 ng stx1 primers, 15 ng stx2 primers, 15 ng eae
primers, 75 ng hlyA primers, 0.18mM each deoxyribonucle-
otide, 4.0mM MgCl2, 50mM Tris-HCl (pH 8.3), 275 ng bovine
serum albumin, 2% sucrose, 0.1mM Cresol Red (Idaho Tech-
Table 1. Source of isolation, genotype, serotype, and year of isolation of Escherichia coli isolates
Genotype Serotype Year
Source 
No. 
isolates STECa
Other
E. coli O26 O103 O111 O128 O145
1976–
1980
1981–
1985
1986–
1990
1991–
1995
1996–
2000
Human 137 37 100 19 23 37 53 5 0 19 4 87 27
Cow 408 140 268 230 65 60 18 35 15 16 37 60 280
T u r k e y 5 1 3 4 8 3 93 80 1 0 3 2 8 2 1 8
Chicken 49 0 49 14 21 10 3 1 5 5 21 5 13
P i g 2 6 3 2 3 972711 0 6 6 1 3
Nonfood animals 81 12 69 11 43 0 13 14 0 19 30 5 27
Totals 752 195 557 286 168 147 94 57 30 68 126 160 368
aSTEC, Shiga toxin–producing E. coli, determined by the presence of stx1 and/or stx2.
Table 2. Class, dilution range, and resistant breakpoints of tested anti-
microbialsa
Class or antimicrobial
Dilution range
tested (µg/mL)
NCCLS resistance 
breakpoint (µg/mL)
Cephalosporins
Cefoxitin 1–32 32
Ceftiofur 1–16 8b
Ceftriaxone 0.06–64 64
Cephalothin 1–32 32
Penicillins
Amoxicillin-clavulanic acid 0.25/0.12–32/16 32/16
Ampicillin 0.25–32 32
Sulfonamides and potentiated sulfonamides
Sulfamethoxazole 32–512 512
Trimethoprim-sulfamethoxazole 0.06/1.19–4/76 4/76
Phenicols
Chloramphenicol 1–32 32
Quinolones and fluoroquinolones
Ciprofloxacin 0.004–8 4
Nalidixic acid 2–256 32
Aminoglycosides
Gentamicin 0.25–16 16
Streptomycin 1–256 64
Tetracycline 1–16 16
aNCCLS, National Committee for Clinical Laboratory Standards. Antimicrobial suscep-
tibility testing was performed according to NCCLS standards (20). Escherichia coli 
(ATCC 25922 and ATCC 35218), Enterococcus faecalis (ATCC 51299), and Pseudomo-
nas aeurigonosa (ATCC 27853) were used as quality controls.
bNCCLS breakpoint not established for E. coli.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1411
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nology, Inc., Salt Lake City, UT), and 0.4 U Taq DNA poly-
merase (PGC Scientifics Corp., Gaithersburg, MD). Reaction
contents were cycled as described (11) after which products
were electrophoresed in 1% agarose gels at 200 V for 30 min
and visualized under ultraviolet light. E. coli O157:H7 (ATCC
43895) was the positive control for all reactions. 
Results
Antimicrobial Resistance Compared to Isolation Source
Of the isolates in this study, the highest frequencies of anti-
microbial-resistant phenotypes were observed for E. coli iso-
lates from humans and turkeys (Figure 1). Fifty-nine percent
of isolates from humans were resistant to sulfamethoxazole,
59% to streptomycin, 56% to ampicillin, 56% to tetracycline,
50% to cephalothin, 38% to trimethoprim-sulfamethoxazole,
34% to chloramphenicol, and 18% to amoxicillin-clavulanic
acid (Figure 1A). Eighty-four percent of isolates from turkeys
were resistant to sulfamethoxazole, followed by 82% to strep-
tomycin, 71% to tetracycline, 49% to ampicillin, 39% to ceph-
alothin, 28% to amoxicillin-clavulanic acid, 24% to
gentamicin, and 20% to nalidixic acid (Figure 1B). Nalidixic
acid-resistant isolates from turkeys were found to have ciprof-
loxacin MICs ranging from 0.12 to >8 µg/mL, whereas each of
the nalidixic acid-susceptible isolates from these animals were
found to have ciprofloxacin MICs of 0.03 µg/mL or less (data
not shown). 
Resistance profiles among isolates from cattle, chicken,
and swine were largely similar to each other (Figure 1). Fifty
percent of isolates from cattle were resistant to streptomycin,
followed by 47% to tetracycline, 46% to sulfamethoxazole,
and 15% to ampicillin (Figure 1C). Seventy-one percent of
isolates from chickens were resistant to streptomycin, fol-
lowed by 63% to tetracycline, 53% to sulfamethoxazole, 20%
to gentamicin, 16% to trimethoprim-sulfamethoxazole, and
12% to ampicillin (Figure 1D). Eighty-one percent of isolates
from swine were resistant to tetracycline, followed by 62% to
streptomycin, 31% to sulfamethoxazole, and 27% to ampicil-
lin (Figure 1E).
Resistance frequencies were lowest for isolates from non-
food animals (Figure 1F); however, 25% were resistant to
streptomycin, 20% to sulfamethoxazole, and 18% to tetracy-
cline. Of these streptomycin-, sulfamethoxazole-, and tetracy-
cline-resistant isolates, 76%, 82%, and 67%, respectively,
were from companion animals.
Of 174 isolates resistant to ampicillin, 73% were resistant
to streptomycin and tetracycline. Of 23 isolates resistant to
cefoxitin, 91% were resistant to amoxicillin-clavulanic acid.
Each of the five ceftiofur-resistant isolates was resistant to
cefoxitin and amoxicillin-clavulanic acid. Based on NCCLS
interpretive criteria for confirmatory ESBL testing (21), none
of the ceftiofur- or cefoxitin-resistant isolates exhibited pheno-
types consistent with ESBL production.
Figure 1. Comparison of antimicrobial resistance frequencies for Escherichia coli isolates from different sources. Am, ampicillin; Cx, cefoxitin; C,
chloramphenicol; Frx, ceftriaxone; Smx, sulfamethoxazole; Cf, cephalothin; Gm, gentamicin; NA, nalidixic acid; Cip, ciprofloxacin; Fur, ceftiofur; Te,
tetracycline; T/S, trimethoprim-sulfamethoxazole; A/C, amoxicillin-clavulanic acid; Str, streptomycin.RESEARCH
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Presence of Virulence Genes 
and Antimicrobial Resistance in STEC
Based on the presence of stx1 and stx2, 26% of the isolates
were characterized as STEC. Of these, 89% contained stx1
only, 2% contained stx2 only, and 9% contained both. Eighty-
one percent of STEC possessed eae and hlyA, 7% eae only,
and 7% hlyA only. Of isolates that were not characterized as
STEC, 34% possessed eae and hlyA, 2% eae only, and 24%
hlyA only (data not shown). 
The highest frequency of STEC was among isolates from
cattle, in which 34% were characterized as STEC, followed by
27% of isolates from humans, 14% of isolates from nonfood
animals, 12% of isolates from swine, and 6% of isolates from
turkeys. None of the isolates from chickens were characterized
as STEC. 
Of E. coli isolates from cattle, resistance frequencies were
generally similar between STEC and other E. coli, respec-
tively, with the exception of ampicillin (26% vs. 8%),
chloramphenicol (14% vs. 4%), cephalothin (14% vs. 3%),
and trimethoprim-sulfamethoxazole (11% vs. 2%), in which
resistance frequencies were noticeably higher (Figure 2A). In
contrast, of isolates from humans, resistance frequencies were
generally lower among STEC isolates compared with other E.
coli (Figure 2B). Specifically, resistance frequencies were
lower in STEC compared with other E. coli, respectively, for
ampicillin (14% vs. 71%), chloramphenicol (5% vs. 44%), sul-
famethoxazole (30% vs. 68%), cephalothin (11% vs. 64%),
tetracycline (32% vs. 63%), trimethoprim-sulfamethoxazole
(8% vs. 48%), amoxicillin-clavulanic acid (5% vs. 22%), and
streptomycin (32% vs. 67%). 
Discussion
Of the 752 E. coli isolates characterized in this study,
approximately half displayed resistance to one or more antimi-
crobials, including penicillins, sulfonamides, cephalosporins,
tetracyclines, and aminoglycosides. These data are in accord
with multiple previous studies suggesting use of these drugs
has been a key factor in the emergence of antimicrobial-resis-
tant E. coli (10–13,27,28). In addition, several other findings
from this study are noteworthy in terms of their public health
importance.
Approximately 40% of E. coli from humans was resistant
to trimethoprim-sulfamethoxazole. Because this drug combi-
nation is recommended for treating a range of human infec-
tions, including complicated urinary tract infections, acute
uncomplicated cystitis, and pyelonephritis (6), E. coli isolates
should be monitored for further dissemination of trimethop-
rim-sulfamethoxazole resistance. Virtually all trimethoprim-
sulfamethoxazole-resistant isolates from this study, however,
were susceptible to ciprofloxacin and ceftriaxone, both of
which are important antimicrobials for treating infections
caused by trimethoprim-sulfamethoxazole-resistant E. coli. 
Ceftiofur is the sole extended-spectrum cephalosporin
approved for use in food animals in the United States, and it is
not approved for use in human clinical medicine (29). The
observation, therefore, that two isolates from humans dis-
played resistance to ceftiofur suggests the transfer of resistant
E. coli from food animals to humans (28,30,31). However,
because these two isolates also displayed resistance or
decreased susceptibility to other β -lactam antimicrobials,
including ampicillin, amoxicillin-clavulanic acid, cephalothin,
cefoxitin, and ceftriaxone, ceftiofur-resistance in these isolates
might have resulted from of β -lactam use in clinical medicine.
Figure 2. Comparison of antimicrobial resistance frequencies between
Shiga toxin-producing Escherichia coli (STEC) and other E. coli. Of iso-
lates from humans, resistance frequencies were generally lower for
STEC compared with other E. coli (A). In contrast, of isolates from cattle,
resistance frequencies were similar between STEC and other E. coli (B).
Am, ampicillin; Cx, cefoxitin; C, chloramphenicol; Frx, ceftriaxone; Smx,
sulfamethoxazole; Cf, cephalothin; Gm, gentamicin; NA, nalidixic acid;
Cip, ciprofloxacin; Fur, ceftiofur; Te, tetracycline; T/S, trimethoprim-sul-
famethoxazole; A/C, amoxicillin-clavulanic acid; Str, streptomycin.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1413
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Similarly, the relatively high number of cefoxitin-resistant iso-
lates from turkeys compared to those from other sources may
be attributable to β -lactam antimicrobial use in turkey produc-
tion. While, based on confirmatory tests, none of the ceftiofur-
or cefoxitin-resistant isolates identified in this study yielded
phenotypes consistent with ESBL production, these isolates
may have produced plasmid-mediated AmpC-like β -lacta-
mases, similar to those described for other E. coli and Salmo-
nella isolated from food animals (28–30). Consequently, work
is ongoing to further characterize the genetic basis of β -lactam
resistance in these isolates.
The observation that 20% of E. coli isolates from turkeys
were resistant to nalidixic acid (concomitant with increased
MICs for ciprofloxacin) is important considering fluoroquinolo-
nes are used to treat a range of E. coli infections in humans (6).
This finding, similar to those of previous reports (14,32,33),
may be largely attributable to fluoroquinolone use in turkeys.
The impact of fluoroquinolones such as enrofloxacin in turkey
production on the emergence of quinolone- and fluoroqui-
nolone-resistant bacteria should continue to be monitored.
Virtually all E. coli isolates from nonfood animals were
susceptible to each of the antimicrobials tested. Notable excep-
tions, however, were isolates from dogs, cats, and rabbits.
While these data yield preliminary evidence suggesting com-
panion animals may be an important reservoir of antimicro-
bial-resistant E. coli of these serotypes, additional studies are
required to more clearly define the impact of antimicrobial use
in companion animal medicine on the emergence of antimicro-
bial-resistant E. coli. 
STEC-associated virulence genes, including stx1, stx2,
eae, and hlyA, were detected primarily in isolates from humans
and cattle. Differences in pathogenicity of STEC for these two
hosts may explain why STEC from humans had a higher fre-
quency of antimicrobial resistance compared to STEC from
cattle. Specifically, because in human clinical medicine anti-
microbials are likely used less often to treat STEC infections
compared with other E. coli infections (6,8), frequencies of
antimicrobial resistance for STEC were generally lower than
those for other E. coli from humans. In contrast to humans,
cattle are asymptomatic carriers of STEC (34); thus the deci-
sion to use antimicrobials in cattle production does not depend
upon whether or not these bacteria are present. Accordingly,
antimicrobial resistance frequencies of STEC and other E. coli
from cattle were largely similar to each other. 
The multiple antimicrobial-resistant phenotypes observed
in this study may have resulted from the spread of mobile
genetic elements. For example, the observation that nearly
75% of ampicillin-resistant E. coli isolates were also resistant
to streptomycin and tetracycline suggests resistance genes for
these drugs are linked on plasmids. Moreover, the widespread
resistance to sulfamethoxazole implies the presence of class I
integrons, which are also important in conferring resistance to
multiple antimicrobials (35). Research is continuing to further
characterize sulfamethoxazole-resistant  E. coli for the pres-
ence of these mobile genetic elements.
Because the isolates from this study were to a large extent
unevenly distributed as to source of isolation versus year of
isolation, analyzing resistance trends over time was not possi-
ble. Likewise, meaningful analysis of antimicrobial resistance
in relation to geographic origin or to serotype was not possi-
ble. Long-term prospective studies examining isolates from
defined geographic locales are required to more precisely
detect temporal and spatial differences in antimicrobial resis-
tance in strains of E. coli. 
Emergence and dissemination of antimicrobial resistance
in E. coli strains of serotypes O26, O103, O111, O128, and
O145 may complicate treatment of certain urinary tract and
enteric infections in humans and animals. Data from this study
did not demonstrate a steadfast link between antimicrobial use
in any particular venue and development of antimicrobial
resistance among these E. coli isolates. The data did, however,
suggest that antimicrobial use in clinical medicine and in agri-
culture was important in the selection of antimicrobial-resis-
tant phenotypes. Continued surveillance of E. coli collected
from agricultural and clinical settings, including the food pro-
duction continuum, is merited to identify emerging antimicro-
bial-resistant phenotypes.
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